Tag Archives: specialty pharma

Big Pharma's "Firepower" Effectively Dropped by 20% in 2013, Says Report

Although Big Pharma’s ‘firepower’ increased last year by $100 billion, it declined in comparison with that of Big Biotech and specialty pharma, according to a new report from EY. EY’s Firepower Index measures companies’ capacity for conducting M&A deals. Firepower is diminished as its market value, cash and equivalents fall or as its debt levels […]
Posted in Strategy | Also tagged , , , | Leave a comment

CEO Interview: Harvey Berger, Ariad Pharmaceuticals

Eight months into the launch of its first approved drug – Iclusig (ponatinib), a small molecule therapy indicated for two rare forms of leukemia – Ariad Pharmaceuticals’ principal founder and CEO Harvey Berger says doing it all, from discovery to global commercialization, is the company’s path to sustainability and the way to take on Big […]
Posted in Biotech, Europe, Gene therapy, Global, leadership, Market Access, Marketing, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , , , , , , , | Leave a comment

Specialty Drugs and Reimbursement

To maximize return on investment, pharma must think strategically about reimbursement channels and how new specialty products will perform in one versus another. By 2018, the amount health insurers spend per person on specialty, or biologic drugs, will equal or surpass the amount spent on traditional products, according to a new report. With the emergence […]
Posted in Biotech, Strategy | Also tagged , , | Leave a comment

Generics Win in an Express Scripts/Medco deal

As a preferred generics supplier to Medco’s mail-order business, Novartis’ Sandoz division, for one, should be waiting with bated breath – and champagne at the ready – for an FTC approval of Express Scripts’ proposed $29.1 billion acquisition of Medco, which would combine two of the three largest pharmacy benefits managers (PBM), according to industry […]
Posted in Deals, pricing, Strategy | Also tagged , , , , , | 4 Comments

With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation

If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the […]
Posted in Deals, Strategy | Also tagged , , , | 3 Comments
  • Categories

  • Meta